Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
The DOI matches its Crossref record; 22 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND Glucokinase acts as a glucose sensor in the pancreas and a glucose processor in the liver, and has a central role in glucose homoeostasis. Dorzagliatin is a new, dual-acting, allosteric glucokinase activator that targets both pancreatic and hepatic glucokinases. Dorzagliatin has good pharmacokinetic and pharmacodynamic properties in humans, and provides effective 24-h glycaemic control and improves glucose sensitivity in patients with type 2 diabetes. We aimed to assess the efficacy and safety of dorzagliatin monotherapy at different doses in Chinese patients with type 2 diabetes. METHODS In this multicentre, randomised, double-blind, placebo-controlled, phase 2 study, we randomly assigned (1:1:1:1:1) patients to receive oral placebo or one of four doses of oral dorzagliatin (75 mg once a day, 100 mg once a day, 50 mg twice a day, or 75 mg twice a day) using permuted-block randomisation, with a block size of ten and without stratification. Eligible patients were men or non-fertile women (aged 40-75 years) with type 2 diabetes who had a BMI of 19·0-30·0 kg/m2, were on a diet and exercise regimen, and were previously untreated or treated with metformin or α-glucosidase inhibitor monotherapy. The study started with a 4-week placebo run-in period followed by a 12-week treatment period. The primary endpoint was the change in HbA1c from baseline to week 12, which was assessed in all patients who received at least one dose of study drug and had both baseline and at least…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In persons with T2D being treated with alpha-glucosidase inhibitors, who develop hypoglycemia due to use of hypoglycemic agents, oral glucose or lactose-containing foods (dairy products) must be given because alpha-glucosidase inhibitors inhibit the breakdown and absorption of complex carbohydrates and disaccharides.1218–1225”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1219]
Citations
Cites
Defining and Characterizing the Progression of Type 2 Diabetes
Fonseca, V. A. (2009) · Diabetes Care · doi:10.2337/dc09-s301 · Cited by 573
Utzschneider, K. M., Prigeon, R. L., Faulenbach, M. V., Tong, J., Carr, D. B., Boyko, E. J., Leonetti, D. L., McNeely, M. J., Fujimoto, W. Y., & Kahn, S. E. (2009) · Diabetes Care · doi:10.2337/dc08-1478 · Cited by 572
Osbak, K. K., Colclough, K., Saint-Martin, C., Beer, N. L., Bellanné-Chantelot, C., Ellard, S., & Gloyn, A. L. (2009) · Human Mutation · doi:10.1002/humu.21110 · Cited by 485
Assessing the potential of glucokinase activators in diabetes therapy
Matschinsky, F. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2850 · Cited by 401
Role of Reduced β-Cell Mass Versus Impaired β-Cell Function in the Pathogenesis of Type 2 Diabetes
Meier, J. J., & Bonadonna, R. C. (2013) · Diabetes Care · doi:10.2337/dcs13-2008 · Cited by 242
Meininger, G. E., Scott, R., Alba, M., Shentu, Y., Luo, E., Amin, H., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2011) · Diabetes Care · doi:10.2337/dc11-1200 · Cited by 213
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Bonadonna, R. C., Heise, T., Arbet‐Engels, C., Kapitza, C., Avogaro, A., Grimsby, J., Zhi, J., Grippo, J. F., & Balena, R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1041 · Cited by 142
Present status of clinical deployment of glucokinase activators
Nakamura, A., & Terauchi, Y. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12294 · Cited by 113
Decreased expression of hepatic glucokinase in type 2 diabetes
Haeusler, R. A., Camastra, S., Astiarraga, B., Nannipieri, M., Anselmino, M., & Ferrannini, E. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.12.007 · Cited by 111
Research works printed but not linked: 3
- Li, 2016, R&D strategies for type 2 diabetes: elucidate the underlying pathology and improve the impaired organ functions, Prog Pharm Sci, 40, 161
- Yu, 2016, Research progress in glucokinase activators, Prog Pharm Sci, 40, 168
- Zhu X-X, Zhu D-L, Li X-Y, et al. Dorzagliatin (HMS5552), a novel dual acting glucokinase activator, improves glycemic control and pancreatic β-cell function in patients with type 2 diabetes: a 28-day treatment study using biomarker-guided patient selection. Diabetes Obes Metab (in press).
Cited by
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Self-citationMultifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Self-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Matschinsky, F. M., & Wilson, D. F. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00148 · Cited by 296
Targeting protein modifications in metabolic diseases: molecular mechanisms and targeted therapies
Wu, X., Xu, M., Geng, M., Chen, S., Little, P. J., Xu, S., & Weng, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01439-y · Cited by 272
Metadata
- Authors
- Zhu, D., Gan, S., Liu, Y., Ma, J., Dong, X., Song, W., Zeng, J., Wang, G., Zhao, W., Zhang, Q., Li, Y., Fang, H., Lv, X., Shi, Y., Tian, H., Ji, L., Gao, X., Zhang, L., Bao, Y., Lei, M., Li, L., Zeng, L., Li, X., Hou, X., Zhao, Y., Hu, T., Ge, X., Zhao, G., Li, Y., Zhang, Y., & Chen, L.
- Affiliations
- Nanjing Drum Tower Hospital (CN)
- The First People's Hospital of Changde (CN)
- Jilin University (CN)
- Nanjing First Hospital (CN)
- Jinan Central Hospital (CN)
- Chenzhou First People's Hospital (CN)
- Sun Yat-sen University (CN)
- First Hospital of Jilin University (CN)
- Affiliated Hospital of Qingdao University (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- Third Hospital of Hebei Medical University (CN)
- Tangshan Gongren Hospital (CN)
- Shanghai Changzheng Hospital (CN)
- Sichuan University (CN)
- Peking University People's Hospital (CN)
- Fudan University (CN)
- Second Hospital of Hebei Medical University (CN)
- Shanghai Jiao Tong University (CN)
- Xiangya Hospital Central South University (CN)
- China Medical University (CN)
- Hua Medicine (China) (CN)
- Corresponding author
- Chen, Li
- ORCID
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 6
- Issue
- 8
- Pages
- 627-636
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2801191096
- Cited by
- 96
- References
- 24
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 18 · 2023: 18 · 2022: 17 · 2021: 11 · 2020: 8 · 2019: 4 · 2018: 4
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Major Scientific and Technological Special Project for Significant New Drugs Development (2014ZX09101002004)
- Shanghai Science and Technology Innovation Action Project (14431908300, 15XD1520500)
- Shanghai Pudong District Science and Technology Innovation Action Project (PKJ2014-S06)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dorzagliatin, type 2 diabetes, glucokinase activators, monotherapy, dose-ranging, HbA1c, glycemic control, Chinese patients, drug safety, adverse events, hypoglycemia, drug-drug interactions, pharmacokinetics, pharmacodynamics, hepatic glucokinase, antidiabetic drugs, metformin
- MeSH terms
- Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Prognosis, Pyrazoles, Biomarkers, Enzyme Activators, Asian People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. https://app.cochat.ai/papers/10.1016/s2213-8587(18)30105-0
- The paper
- Zhu, D., Gan, S., Liu, Y., Ma, J., Dong, X., Song, W., Zeng, J., Wang, G., Zhao, W., Zhang, Q., Li, Y., Fang, H., Lv, X., Shi, Y., Tian, H., Ji, L., Gao, X., Zhang, L., Bao, Y., . . . Chen, L. (2018). Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(18)30105-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.